Akebia Therapeutics (NASDAQ:AKBA) announces positive results from the two Phase 3 clinical trials in its INNO2VATE
program comparing vadadustat to darbepoetin alfa (similar to
erythropoietin) in adult patients on dialysis with chronic kidney
disease-related anemia.
Both studies met the primary and secondary
endpoints demonstrating vadadustat’s non-inferiority to darbepoetin alfa
as measured by the mean change in hemoglobin from baseline to weeks 24 –
36 (secondary evaluation period was weeks 40 – 52).
The company plans to file a U.S. marketing application “as quickly as possible.”
https://seekingalpha.com/news/3569012-akebia-up-25-premarket-on-positive-vadadustat-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.